Reactive thrombocytocis
Reading File
Reactive thrombocytosis (also called secondary thrombocytosis) is a platelet count elevation driven by an underlying condition, in contrast to clonal/primary thrombocytosis. Let me pull up the authoritative textbook content now.
Searching sources...
Finding Sources
Finding Sources
Searching PubMed
reactive thrombocytosis secondary thrombocytosis
Good results found. Let me now read the key textbook sections in parallel.
Reading File
Reading File
Reading File
Good textbook data retrieved. Let me also get the Henry's section on the topic and the Washington Manual for more details on pathophysiology and lab findings.
Finding Sources
Finding Sources
Reading File
Reading File
Excellent - I now have the key comparison table and comprehensive content. Let me compile the full answer.
Reactive Thrombocytosis (Secondary Thrombocytosis)
Definition
Thrombocytosis is defined by the WHO as a platelet count >450 × 10⁹/L. Reactive (secondary) thrombocytosis is an elevation in platelet count driven by an underlying systemic condition, as opposed to primary (clonal) thrombocytosis arising from autonomous bone marrow disorders (MPNs, myelodysplastic syndrome).
- Washington Manual of Medical Therapeutics, p. 764
- Henry's Clinical Diagnosis and Management by Laboratory Methods
Pathogenesis
In most patients, thrombocytosis is acquired. The rare inherited forms result from gain-of-function mutations in thrombopoietin (TPO) or its receptor (MPL). In reactive thrombocytosis, the platelet count rises in response to:
- Cytokines (particularly interleukins such as IL-6) released during inflammation or tissue injury, which stimulate megakaryocyte proliferation via TPO
- Reduced splenic sequestration (post-splenectomy) - platelets that would normally pool in the spleen are released into circulation
- Iron deficiency - the mechanism is incompletely understood but may involve uncoupled megakaryocyte maturation
Causes
| Category | Examples |
|---|---|
| Infection / Inflammation | Sepsis, osteomyelitis, rheumatoid arthritis, IBD, Kawasaki disease |
| Iron deficiency anemia | Most common cause in children |
| Malignancy | Solid tumors (especially GI, lung, ovarian) |
| Post-splenectomy | Persistent; platelets no longer pooled in spleen |
| Tissue damage / Trauma | Surgery, burns, fractures |
| Hemolysis | Hemolytic anemias |
| Rebound thrombocytosis | Recovery from thrombocytopenia (alcohol withdrawal, B12/folate repletion, after chemotherapy) |
- Quick Compendium of Clinical Pathology, p. 239
- Washington Manual, p. 764
Clinical Features and Risk
A key distinguishing point from clonal thrombocytosis:
No increased risk of thrombosis or hemorrhage in reactive thrombocytosis, even at very high platelet counts.
However, one important exception: reactive thrombocytosis occurring during ICU recovery has been associated with an increased incidence of venous thromboembolism (~10% of cases) - particularly when additional risk factors (malignancy, immobility, central catheters) are present. - Henry's, citing Ho et al., 2012
There is no splenomegaly, no erythromelalgia, and no microvascular ischemia.
Distinguishing Reactive vs. Clonal Thrombocytosis
| Finding | Clonal Thrombocytosis (ET/MPN) | Reactive Thrombocytosis |
|---|---|---|
| Underlying systemic disease | No | Often clinically apparent |
| Digital / cerebrovascular ischemia | Characteristic | No |
| Large-vessel thrombosis | Increased risk | No |
| Bleeding complications | Increased risk | No |
| Splenomegaly | ~40% of patients | No |
| Peripheral blood smear | Giant, abnormal platelets | Normal platelets |
| Platelet function | May be abnormal | Normal |
| BM megakaryocytes (morphology) | Giant, dysplastic, increased ploidy | Normal morphology |
| JAK2/CALR/MPL/BCR-ABL1 mutations | Present | Absent |
Modified from Schafer AI, N Engl J Med 2004; as cited in Henry's Clinical Diagnosis and Management
Laboratory Findings
- Elevated platelet count (may be markedly elevated, >1000 × 10⁹/L in extreme cases)
- Peripheral smear: normal platelet morphology (no giant or dysplastic platelets)
- No clonal markers: JAK2 V617F, CALR, MPL mutations are absent
- May show features of underlying cause: elevated CRP/ESR (inflammation), low ferritin/microcytic anemia (iron deficiency), leukocytosis (infection)
- Platelet function tests: normal
- Bone marrow (if done): increased megakaryocytes with normal morphology (contrast with ET where giant dysplastic megakaryocytes are seen)
Note: Extreme thrombocytosis (>1000 × 10⁹/L) can occur in both reactive and clonal etiologies - the platelet count alone is not a reliable discriminator.
Management
- Treat the underlying cause - platelet count normalizes once the causative condition resolves
- No cytoreductive therapy is needed for reactive thrombocytosis
- If thrombotic complications occur despite a reactive picture, reassess for an occult MPN
- Post-splenectomy thrombocytosis is typically persistent but benign; low-dose aspirin is sometimes used empirically
Diagnosis of Essential Thrombocythemia (ET) by Exclusion
For ET diagnosis (WHO 2016 criteria), all four must be met:
- Platelet count ≥450 × 10⁹/L
- BM biopsy: increased mature megakaryocytes, no excess erythropoiesis or granulopoiesis, no reticulin >grade I
- Exclusion of BCR-ABL1+ CML, PV, myelofibrosis, MDS
- JAK2 V617F, CALR, or MPL mutation present - OR if absent, no evidence for reactive thrombocytosis
This means reactive thrombocytosis must be actively excluded before diagnosing ET.
- Washington Manual, p. 764-765
This is a shared conversation. Sign in to Orris to start your own chat.